Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
August 22, 2022 11:14 AM EDTUpdated 01:16 PM
R&D

Look­ing to so­lid­i­fy semaglu­tide's reign over GLP-1, No­vo Nordisk posts key PhII win

Amber Tong

No­vo Nordisk is one step clos­er to un­lock­ing a new semaglu­tide fran­chise — one it hopes can spur even bet­ter re­sults for peo­ple with type 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times